Literature DB >> 20065499

Efficacy of tramadol in combination with doxepin or venlafaxine in inhibition of nociceptive process in the rat model of neuropathic pain: an isobolographic analysis.

A Wrzosek1, I Obara, J Wordliczek, B Przewlocka.   

Abstract

Neuropathic pain constitutes a serious therapeutic problem. In most cases polytherapy is necessary. Tramadol and antidepressants have common mechanisms of action and are frequently used together in clinical practice, thus interaction between them is very important. In the present study isobolographic analysis for equivalent doses of drugs was applied to examine the nature of interaction between tramadol and doxepin or venlafaxine in a neuropathic pain model in rats. Allodynia and hyperalgesia were assessed after intraperitoneal administration of each drug alone or in combination. Dose response curves were obtained and ED(50) doses were calculated. All drugs were effective in reducing thermal hyperalgesia and mechanical allodynia, however doxepin was more effective than venlafaxine. Combined administration of tramadol and doxepin demonstrated synergistic action in reducing thermal hyperalgesia and additive action in reducing mechanical allodynia. Combined administration of tramadol and venlafaxine showed additive action in reducing hyperalgesia and allodynia. Moreover, combined administration of tramadol and doxepin was more effective than combined administration of tramadol and venlafaxine. The experiments demonstrated that the nature of interaction between tramadol and doxepin is synergistic, which is not the case for tramadol and venlafaxine, what provides a valuable information referring to clinical practice, rationalizing administration of such drug combination.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20065499

Source DB:  PubMed          Journal:  J Physiol Pharmacol        ISSN: 0867-5910            Impact factor:   3.011


  8 in total

1.  Effects of venlafaxine and escitalopram treatments on NMDA receptors in the rat depression model.

Authors:  Nigar Yilmaz; Arif Demirdas; Mustafa Yilmaz; Recep Sutcu; Aynur Kirbas; Medine Cumhur Cure; Ibrahim Eren
Journal:  J Membr Biol       Date:  2011-07-14       Impact factor: 1.843

Review 2.  Revisiting Tramadol: A Multi-Modal Agent for Pain Management.

Authors:  Ahmed Barakat
Journal:  CNS Drugs       Date:  2019-05       Impact factor: 5.749

3.  Tramadol and propentofylline coadministration exerted synergistic effects on rat spinal nerve ligation-induced neuropathic pain.

Authors:  Jin Zhang; Dan Wu; Cheng Xie; Huan Wang; Wei Wang; Hui Zhang; Rui Liu; Li-Xian Xu; Xiao-Peng Mei
Journal:  PLoS One       Date:  2013-08-29       Impact factor: 3.240

Review 4.  Depression and chronic pain in the elderly: links and management challenges.

Authors:  Panagiotis Zis; Argyro Daskalaki; Ilia Bountouni; Panagiota Sykioti; Giustino Varrassi; Antonella Paladini
Journal:  Clin Interv Aging       Date:  2017-04-21       Impact factor: 4.458

5.  Repurposing Doxepin to Ameliorate Steatosis and Hyperglycemia by Activating FAM3A Signaling Pathway.

Authors:  Zhenzhen Chen; Xiangyang Liu; Yanjin Luo; Junpei Wang; Yuhong Meng; Lei Sun; Yongsheng Chang; Qinghua Cui; Jichun Yang
Journal:  Diabetes       Date:  2020-04-20       Impact factor: 9.461

6.  Doxepin prevents the Expression and Development of Paclitaxel-Induced Neuropathic Pain.

Authors:  Hajar Naji Esfahani; Golnaz Vaseghi; Shaghayegh Haghjooy Javanmard; Aliasghar Pilehvarian
Journal:  Adv Biomed Res       Date:  2021-11-26

7.  Venlafaxine Attenuates Heat Hyperalgesia Independent of Adenosine or Opioid System in a Rat Model of Peripheral Neuropathy.

Authors:  Alireza Abed; Valiollah Hajhashemi; Hamid Reza Banafshe; Mohsen Minaiyan; Azam Mesdaghinia
Journal:  Iran J Pharm Res       Date:  2015       Impact factor: 1.696

8.  Evaluation of the central and peripheral effects of doxepin on carrageenan-induced inflammatory paw edema in rat.

Authors:  Mohsen Zabihi; Valiollah Hajhashemi; Mohsen Minaiyan; Ardeshir Talebi
Journal:  Res Pharm Sci       Date:  2017-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.